ICH M13A: Changes to Step 2 [BE/BA News]

posted by BEQool  – 2024-09-09 07:48 (243 d 01:17 ago) – Posting: # 24191
Views: 4,645

Hello all,

❝   – Final (page 12)

❝     Randomised, non-replicate, crossover design studies should be analysed using an appropriate parametric method, e.g., general linear model (GLM) or mixed model.

❝     […] The mixed model likely was a concession made to the FDA and Health Canada, the only agencies currently requiring it.


So we can either put subject as a fixed or random effect?

But then the following text comes up:
"The primary statistical analyses should include all data for all subjects who provide evaluable data for both the test and comparator products."

And also in Q&A document:
In a 2-way crossover design, if data from one period are excluded, the subject should not be included in the statistical analysis […]

I am confused, if I understand well, we should all treat subject as a fixed effect? :confused:

Regards
BEQool

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
138 visitors (0 registered, 138 guests [including 11 identified bots]).
Forum time: 09:06 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5